Prevention, Early Detection, and Alzheimer’s Disease Risk
Prevention is more than general brain health and lifestyle.
Healthy habits such as regular exercise, blood-pressure control, good sleep, social connection, and a heart-healthy diet can support brain health and may help reduce the risk of cognitive decline. Learn more about Brain Health and Healthy Aging.
But prevention research also focuses on identifying Alzheimer’s disease risk and Alzheimer’s-related brain changes before memory symptoms become disabling. This can include family-history review, genetic-risk information, biomarker testing, and research studies for people who may have no symptoms at all.
Alzheimer’s disease-related changes can begin years before noticeable memory problems develop. This is why some prevention and early-detection studies enroll people who are cognitively normal but may have a family history of Alzheimer’s disease, genetic risk factors, or biological evidence of increased risk.
Family History and Alzheimer’s Disease Risk
Many people are concerned about Alzheimer’s disease because a parent, sibling, or other close relative was affected.
A family history of Alzheimer’s disease can increase concern and may increase risk, but it does not mean that a person will develop Alzheimer’s disease. Most Alzheimer’s disease that begins later in life is influenced by a combination of age, genes, medical conditions, lifestyle factors, and other factors that are not fully understood.
Family patterns can still be important. Alzheimer’s disease that affects several close relatives, especially when symptoms begin at an unusually young age, may warrant more detailed discussion about genetics and inherited forms of dementia.
Most Alzheimer’s disease is not caused by a single inherited gene mutation. Rare inherited forms of Alzheimer’s disease can occur in families and may begin much earlier than typical late-onset Alzheimer’s disease.
APOE and Genetic Risk
The APOE gene is one of the most important genetic risk factors associated with late-onset Alzheimer’s disease.
Every person inherits two copies of the APOE gene. The most common forms are called APOE ε2, APOE ε3, and APOE ε4.
APOE ε4 is associated with an increased risk of developing Alzheimer’s disease. Having one copy of APOE ε4 may increase risk, and having two copies may increase risk further. However, APOE ε4 is not a diagnosis of Alzheimer’s disease and does not mean that a person will definitely develop dementia.
Many people who carry APOE ε4 never develop Alzheimer’s disease. Many people who develop Alzheimer’s disease do not carry APOE ε4.
APOE testing may be useful in selected situations, including clinical research screening, discussion of treatment-related risk, or evaluation of someone who wants to better understand a prior genetic result. APOE results should be interpreted carefully and in the context of personal and family history, medical conditions, cognitive symptoms, and other available information.
Genetic Risk Is Not the Same as Alzheimer’s Disease
Genetic testing and biomarker testing answer different questions.
APOE testing provides information about inherited risk. It does not show whether Alzheimer’s disease changes are currently present in the brain.
Biomarker testing looks for biological evidence that may be associated with Alzheimer’s disease. Depending on the situation, this may include blood-based biomarkers, cerebrospinal-fluid testing, amyloid PET imaging, or tau PET imaging.
A person may have an APOE-related risk factor without having Alzheimer’s disease biomarkers. A person may also have Alzheimer’s-related biomarker changes without carrying APOE ε4.
No single test should be interpreted in isolation. Results should be considered together with symptoms, cognitive testing, medical history, family history, and other clinical information.
Biomarkers and Early Detection
Alzheimer’s disease is associated with abnormal accumulation of amyloid and tau proteins in the brain.
These changes may begin years before a person develops clear memory symptoms. Biomarker testing can sometimes help clarify whether Alzheimer’s-related changes may be present before dementia develops.
Depending on the individual situation, testing may include:
- Blood-based biomarkers, including p-tau and amyloid-related blood tests
- Cerebrospinal-fluid testing obtained through lumbar puncture
- Amyloid PET imaging
- Tau PET imaging
- MRI or other structural brain imaging
These tests are not necessary for every person with a family history of Alzheimer’s disease or concern about future risk.
They may be helpful when someone has memory symptoms, when the diagnosis is uncertain, when disease-modifying treatment is being considered, when a person is interested in clinical research, or when further clarification of Alzheimer’s disease risk or biology may be appropriate.
Prevention Research and Clinical Trials
Prevention research is helping scientists understand whether Alzheimer’s disease can be delayed, slowed, or prevented before significant symptoms develop.
Studies may include medications, infusions, injections, lifestyle programs, imaging, cognitive testing, blood biomarkers, genetic-risk assessment, digital assessments, or other approaches designed to identify or reduce Alzheimer’s-related risk.
A person does not need to have dementia—or even memory symptoms—to be considered for certain prevention or early-detection research studies.
Some studies are designed for people who:
- Have no significant memory symptoms
- Have a parent, sibling, or multiple relatives with Alzheimer’s disease
- Carry APOE ε4 or are interested in learning whether genetic-risk testing may be appropriate
- Have amyloid or other Alzheimer’s-related biomarker findings
- Have mild memory concerns but remain independent
- Want to learn about prevention, early-detection, or biomarker research opportunities
Participation in research is always voluntary. Not every person will qualify for every study, and eligibility depends on the specific requirements of each research program.
Who May Wish to Learn More?
You may wish to learn more about prevention and early detection if:
- You have a family history of Alzheimer’s disease
- Alzheimer’s disease occurred unusually early in your family
- You are interested in APOE genetic-risk testing or want help understanding a previous result
- You have no symptoms but are interested in prevention research
- You have mild memory concerns and want to understand whether further evaluation or biomarker testing may be appropriate
- You want to learn whether you may qualify for an Alzheimer’s disease research study
Interested in Prevention or Early-Detection Research?
The Alzheimer’s Disease Research Center of Albany offers information about current research opportunities for people with memory concerns, mild cognitive impairment, Alzheimer’s disease, family-history risk, genetic risk, or no symptoms.
